Background/objectives: Evaluate the mid-term outcomes of the PAUL Glaucoma Implant (PGI) in the management of uveitic glaucoma.
Subjects/methods: This was a single-centre, multi-surgeon, retrospective analysis of 50 consecutive cases of PGI for uveitic glaucoma performed between April 2019 and August 2021. Primary outcomes include: complete and qualified success (IOP ≥5 mmHg to ≤21 mmHg with ≥20% IOP reduction) or failure (IOP exceeding the success criteria, additional glaucoma procedures, no perception of light vision). Secondary outcomes included: visual acuity, IOP, medications, complications and intraluminal stent removal.
Results: We included 50 eyes of 41 patients. Mean age was 45.8 ± 19.8 years (range 6-81 years) in this heterogenous and complex cohort. Mean pre-op IOP was 30.6 ± 9.8 mmHg on 3.9 ± 0.9 medications. In total, 62% of patients were on acetazolamide, and 64% required systemic immunosuppression. At final follow-up (mean: 35.8 ± 9.8 months, range 5-58 months), IOP and medications were significantly reduced (12.2 ± 4.4 mmHg, requiring 1.1 ± 1.3 medications, p < 0.0001). Resulting in 48% complete and 92% qualified success rates. Failure occurred in 8% of cases, 6% due to hypertension but only one case of prolonged hypotony (2%).
Conclusions: To date, this study represents the first publication looking specifically at the efficacy and safety of the PGI in the management of complex uveitic glaucoma. With an average follow-up of 3 years, it shows high levels of complete and qualified success with few complications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41433-024-03527-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In Vitro Analysis of Pressure Resistance in the Paul Glaucoma Implant and Ahmed ClearPath 250 With and Without Polypropylene Thread Inside the Tube.
Transl Vis Sci Technol
January 2025
Department of Ophthalmology, Shimane University Faculty of Medicine, Izumo, Japan.
Purpose: Pressure resistance characteristics of the Paul glaucoma implant (PGI) and Ahmed ClearPath 250 (ACP), with and without the insertion of polypropylene thread in their tubes, were evaluated.
Methods: The in vitro flow pressure was evaluated at varying flow rates, both with and without threads (6-0 for PGI and 4-0 or 3-0 for ACP). Cross-sectional areas of the tube lumen and thread were measured to calculate pressure resistance using the Hagen-Poiseuille equation.
Sonographic bleb visualisation after PAUL glaucoma implant surgery.
Br J Ophthalmol
December 2024
Department of Ophthalmology, University of Bonn, Bonn, Germany.
Background/aims: Bleb characteristics in the area around the plate following glaucoma drainage device (GDD) surgery are difficult to evaluate on slit lamp examination. Ultrasound sonography could be used for more detailed visualisation. The aim of this study was to describe bleb configuration after PAUL glaucoma implant (PGI) surgery and evaluate the possible correlation with intraocular pressure (IOP) in order to derive new markers for evaluating GDD function.
View Article and Find Full Text PDFAnterior segment OCT for imaging PAUL glaucoma implant patch grafts: a useful method for follow-up and risk management.
Graefes Arch Clin Exp Ophthalmol
December 2024
Department of Ophthalmology, University Hospital Bonn, Ernst-Abbe-Str. 2, 53127, Bonn, Germany.
Aim: To evaluate a useful, non-contact method for the follow-up of pericardium patch graft changes in patients undergoing PAUL Glaucoma Implant (PGI) surgery using high-resolution anterior segment optical coherence tomography (OCT) to predict tube erosions.
Methods: Prospective analysis over six months of tube pericardium patch graft thickness of PGI surgical cases at the University Eye Hospital Bonn, Germany, from November 2021 to August 2022. In all eyes, Tutopatch (RTI Surgical, United States) pericardium was used to cover the implant intra-operatively.
Efficacy and Safety of a Fixed-Dose Combination of Brinzolamide 1%/Timolol 0.5% vs. Dorzolamide 2%/Timolol 0.5% in Indian Patients With Primary Open-Angle Glaucoma or Ocular Hypertension: A Randomized Phase 3 Study.
Cureus
November 2024
Medical Affairs, Sun Pharma Laboratories Limited, Mumbai, IND.
Introduction Fixed-dose combinations (FDCs) have the potential in glaucoma management to improve efficacy due to the complementary mechanism of action of the drugs as well as compliance while reducing adverse effects by minimizing exposure to preservatives and the financial burden on the patients. FDC of brinzolamide/timolol has demonstrated efficacy and safety in multinational phase 3 studies in primary open-angle glaucoma (POAG) and ocular hypertension. However, efficacy and safety in the Indian population are not known.
View Article and Find Full Text PDFSubretinal Gene Therapy Drug AGTC-501 for XLRP Phase 1/2 Multicenter Study (HORIZON): 24-Month Safety and Efficacy Results: Subretinal Gene Therapy AGTC-501 for XLRP Ph 1/2 24M Results.
Am J Ophthalmol
December 2024
Astellas Pharma US, Inc., Northbrook, Illinois, USA; Beacon Therapeutics, Alachua, Florida, USA. Electronic address:
Purpose: To evaluate the safety and efficacy of subretinal gene therapy using AGTC-501 (rAAV2tYF-GRK1-RPGR) in male participants with X-linked retinitis pigmentosa (XLRP).
Design: Phase 1/2, open-label, dose-escalation study.
Methods: Setting: Four centers in the United States.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!